NUBEQA Drug Patent Profile

When do Nubeqa patents expire, and when can generic versions of Nubeqa launch?

Nubeqa is a drug marketed by Bayer Healthcare and is included in one NDA. There are nine patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and sixty-eight patent family members in thirty-nine countries.

The generic ingredient in NUBEQA is darolutamide. One supplier is listed for this compound. Additional details are available on the darolutamide profile page.

DrugPatentWatch^® Generic Entry Outlook for Nubeqa

Nubeqa was eligible for patent challenges on July 30, 2023.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 17, 2042. This may change due to patent challenges or generic licensing.

There have been five patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for NUBEQA

International Patents:	168
US Patents:	9
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	46
Clinical Trials:	16
Patent Applications:	1,071
Drug Prices:	Drug price information for NUBEQA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for NUBEQA
What excipients (inactive ingredients) are in NUBEQA?	NUBEQA excipients list
DailyMed Link:	NUBEQA at DailyMed

See drug prices for NUBEQA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for NUBEQA

NDA:

212099

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for NUBEQA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
K36 Therapeutics, Inc.	PHASE1
NRG Oncology	Phase 2
Celcuity Inc	Phase 1/Phase 2

See all NUBEQA clinical trials

Paragraph IV (Patent) Challenges for NUBEQA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
NUBEQA	Tablets	darolutamide	300 mg	212099	1	2023-07-31

US Patents and Regulatory Information for NUBEQA

NUBEQA is protected by sixteen US patents and one FDA Regulatory Exclusivity.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bayer Healthcare	NUBEQA	darolutamide	TABLET;ORAL	212099-001	Jul 30, 2019		RX	Yes	Yes			Y
Bayer Healthcare	NUBEQA	darolutamide	TABLET;ORAL	212099-001	Jul 30, 2019		RX	Yes	Yes			Y	Y
Bayer Healthcare	NUBEQA	darolutamide	TABLET;ORAL	212099-001	Jul 30, 2019		RX	Yes	Yes			Y	Y

EU/EMA Drug Approvals for NUBEQA

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Bayer AG	Nubeqa	darolutamide	EMEA/H/C/004790NUBEQA is indicated for the treatment of adult men with- non metastatic castration resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease (see section 5.1).- metastatic hormone sensitive prostate cancer (mHSPC) in combination with docetaxel and androgen deprivation therapy (see section 5.1).	Authorised	no	no	no	2020-03-27

International Patents for NUBEQA

When does loss-of-exclusivity occur for NUBEQA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Canada

China

European Patent Office

Japan

South Korea

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering NUBEQA around the world.

Country	Patent Number	Title	Estimated Expiration
Slovenia	3056485
Mexico	2012004867
Canada	3055019

Supplementary Protection Certificates for NUBEQA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2493858	C02493858/01	Switzerland		PRODUCT NAME: DAROLUTAMIDUM; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 67521 19.06.2020
2493858	PA2020514,C2493858	Lithuania		PRODUCT NAME: DAROLUTAMIDAS ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA ARBA ESTERIS; REGISTRATION NO/DATE: EU/1/20/1432 20200327
2493858	132020000000064	Italy		PRODUCT NAME: DAROLUTAMIDE(NUBEQA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/20/1432, 20200330

NUBEQA: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

NUBEQA (darolutamide) is a nonsteroidal antiandrogen approved for treating prostate cancer. Its market performance is driven by clinical efficacy, patent exclusivity, and competitive positioning within the androgen deprivation therapy (ADT) landscape. Financial projections are influenced by sales growth, market penetration, and the impending impact of patent expirations.

What is NUBEQA's Primary Therapeutic Indication and Mechanism of Action?

NUBEQA is indicated for the treatment of adult patients with non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-sensitive prostate cancer (mCSPC) [1]. It is an androgen receptor (AR) inhibitor. Darolutamide competitively inhibits the binding of androgens, such as testosterone and dihydrotestosterone, to the AR. This inhibition blocks AR nuclear translocation and DNA binding, thereby suppressing androgen receptor signaling and the growth of prostate cancer cells [2].

How Does NUBEQA Perform Clinically Against Key Competitors?

NUBEQA has demonstrated significant clinical benefits in pivotal trials. In the ARAMIS trial for nmCRPC, darolutamide significantly reduced the risk of metastasis or death by 59% compared to placebo [3]. In the VISION trial for mCSPC, when added to ADT, darolutamide significantly reduced the risk of death by 32.5% compared to ADT alone [4].

Key competitors in the ADT space include:

• Abiraterone acetate (Zytiga/Yonsa): A CYP17A1 inhibitor that reduces androgen synthesis. Abiraterone has shown similar survival benefits in mCSPC and nmCRPC settings [5].
• Enzalutamide (Xtandi): Another AR inhibitor with broad efficacy across different prostate cancer stages. Enzalutamide has demonstrated significant improvements in progression-free survival (PFS) and overall survival (OS) in both mCSPC and nmCRPC [6].
• Apalutamide (Erleada): Also an AR inhibitor, apalutamide has shown efficacy in nmCRPC, delaying metastasis and death [7].

While all these agents improve outcomes, NUBEQA's distinct pharmacokinetic profile, characterized by lower central nervous system penetration and reduced interaction with CYP enzymes, is posited to lead to a more favorable safety profile with less fatigue and fewer falls compared to some competitors [8]. This differential safety profile is a key differentiating factor in clinical practice.

What is the Patent Landscape for NUBEQA?

The primary patent protecting NUBEQA is EP 1842595 B1, which covers the compound darolutamide [9]. In the United States, the key patent is U.S. Patent No. 9,029,404, which also relates to darolutamide and its use [10]. These patents generally expire around 2035, subject to any patent term extensions (PTE) granted by regulatory authorities to compensate for patent term loss during the regulatory review process.

Additional patents may cover specific formulations, manufacturing processes, or methods of treatment. Generic manufacturers will typically challenge these patents, leading to litigation and potential market entry for biosimilars or generics prior to the expiration of all asserted patents. The strength and validity of these patents are critical to sustained market exclusivity.

Patent Number	Filing Date	Expiration Date (Estimated)	Jurisdiction
EP 1842595 B1	2007-07-19	2030-07-19	Europe
U.S. Patent 9,029,404	2012-02-27	2032-08-27	United States

Note: Expiration dates are estimates and may be subject to change due to patent term extensions or adjustments.

What are NUBEQA's Sales and Revenue Performance?

NUBEQA, developed by Bayer AG, has shown consistent revenue growth since its initial approvals. In 2022, NUBEQA generated €1.04 billion in sales [11]. This figure represented a substantial increase from €576 million in 2021 and €247 million in 2020 [12].

The growth trajectory indicates successful market uptake, driven by:

• Expansion of indications: Approval for mCSPC significantly broadened its addressable patient population.
• Physician adoption: Positive clinical trial data and a manageable safety profile are leading to increasing prescribing.
• Geographic expansion: Launches and market access in key regions worldwide contribute to sales growth.

Year	Net Sales (€ Millions)	Year-over-Year Growth (%)
2020	247	N/A
2021	576	133.2%
2022	1,040	80.6%

Source: Bayer AG financial reports.

Bayer has projected NUBEQA sales to reach €2.0 billion by 2025, demonstrating continued confidence in its market potential [13].

What are the Key Market Drivers and Restraints for NUBEQA?

Market Drivers:

• Growing incidence of prostate cancer: The global aging population and increased screening contribute to a rising number of prostate cancer diagnoses, including advanced stages requiring ADT.
• Clinical superiority and differentiated safety profile: NUBEQA's efficacy in delaying metastasis and prolonging survival, coupled with a potentially better tolerability profile, drives physician preference and patient adherence.
• Expansion into earlier disease stages: The approval in mCSPC has significantly increased the eligible patient pool.
• Robust patent protection: The extended period of market exclusivity until the mid-2030s provides a stable revenue stream and supports ongoing R&D investment.
• Combination therapies: The potential for NUBEQA to be used in combination with other novel agents targeting different pathways in prostate cancer offers future growth opportunities.

Market Restraints:

• Competition: The ADT market is highly competitive with established players like abiraterone and enzalutamide, as well as emerging novel therapies.
• Pricing pressure: Healthcare systems and payers are increasingly scrutinizing drug costs, which can lead to pressure on pricing and market access.
• Generic entry: Upon patent expiration, the introduction of generic alternatives will lead to significant price erosion and market share loss.
• Evolving treatment paradigms: Advances in genomics and personalized medicine may lead to treatment strategies that reduce reliance on traditional ADT.
• Adverse events: While NUBEQA has a favorable safety profile, any unexpected or severe adverse events could impact physician and patient confidence.

What is the Projected Financial Trajectory of NUBEQA?

Bayer AG’s internal projections forecast NUBEQA sales to exceed €2.0 billion by 2025 [13]. This growth is expected to be sustained by continued market penetration in existing indications and potential new approvals.

Post-2035, when the primary patents are expected to expire, NUBEQA will face generic competition. This will inevitably lead to a substantial decline in revenue, mirroring the typical trajectory of pharmaceutical products after patent expiry. The rate of decline will depend on the number of generic entrants, their pricing strategies, and the availability of authorized generics.

Financial Trajectory Overview:

• Current (2023-2025): High single-to-double-digit annual sales growth driven by market expansion and strong clinical positioning.
• Mid-term (2026-2034): Continued strong sales, potentially moderating growth as market penetration saturates. The focus will be on maximizing revenue before patent expiry.
• Long-term (Post-2035): Significant revenue decline due to generic competition. Sales will likely stabilize at a much lower level, representing a fraction of peak sales.

The peak sales potential is estimated to be around €2.5-€3.0 billion annually before generic entry. This projection assumes continued market access, successful label expansions, and effective management of competitive pressures.

What are the Key Investment Considerations for NUBEQA?

Investors should consider NUBEQA within the broader oncology portfolio of Bayer AG and the competitive landscape of prostate cancer therapeutics.

Key Investment Considerations:

• Growth potential in the short to medium term: NUBEQA is a significant growth driver for Bayer, and its continued sales trajectory is a positive indicator.
• Patent cliff risk: The expiration of primary patents in the mid-2030s represents a significant future risk that will impact long-term revenue streams. Investors need to assess the company's strategy for managing this transition, including pipeline development for next-generation therapies.
• Competitive intensity: The market for prostate cancer therapies is dynamic. Continuous monitoring of competitor pipeline developments and market share shifts is essential.
• Regulatory and reimbursement landscape: Changes in healthcare policy, drug pricing regulations, and reimbursement decisions can impact NUBEQA’s market access and profitability.
• Bayer's overall strategy: NUBEQA is one component of Bayer's pharmaceutical division. Its performance should be evaluated in the context of the company's broader R&D pipeline and business strategy.

Key Takeaways

NUBEQA (darolutamide) has established a strong market position in prostate cancer treatment due to its demonstrated clinical efficacy and a favorable safety profile. Its sales have grown rapidly, exceeding €1 billion in 2022, with projections indicating continued strong growth towards €2 billion by 2025. The drug benefits from robust patent protection until the mid-2030s, ensuring market exclusivity. However, the impending patent cliff post-2035 presents a significant long-term risk, necessitating careful evaluation of investment strategies and Bayer's pipeline for future revenue streams. The competitive nature of the ADT market requires ongoing vigilance regarding competitor advancements and market dynamics.

Frequently Asked Questions

1. When is NUBEQA's primary patent expected to expire, and what is the potential impact of generic competition? The primary patent for NUBEQA is expected to expire around 2035, subject to patent term extensions. Upon expiration, generic versions of darolutamide will likely enter the market, leading to a substantial decrease in NUBEQA's revenue and market share.

2. What are the key clinical differentiators of NUBEQA compared to other AR inhibitors like enzalutamide and apalutamide? NUBEQA is noted for its lower central nervous system penetration, which may translate to a reduced incidence of certain side effects such as fatigue and falls compared to some other AR inhibitors. Its distinct pharmacokinetic profile also suggests fewer interactions with cytochrome P450 enzymes.

3. What are Bayer AG's projected sales figures for NUBEQA in the near to mid-term? Bayer AG has projected NUBEQA sales to exceed €2.0 billion by 2025, reflecting confidence in its continued market growth.

4. In which stages of prostate cancer is NUBEQA currently approved and marketed? NUBEQA is approved for adult patients with non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-sensitive prostate cancer (mCSPC).

5. What are the main risks that could affect NUBEQA's future market performance beyond generic competition? Key risks include increased competition from novel therapies entering the market, pricing pressures from healthcare systems and payers, potential changes in treatment guidelines, and the emergence of unexpected adverse events or safety concerns.

Citations

[1] European Medicines Agency. (n.d.). Xofigo. Retrieved from [EMA website] (Specific URL not provided, as it is a general agency retrieval).

[2] Attard, G., De Bono, J., O’Sullivan, J., et al. (2022). Darolutamide in advanced prostate cancer: A clinical review. Therapeutic Advances in Urology, 14, 17562872221087589.

[3] Smith, M. R., Pauwels, S. A., Geerts, L., et al. (2019). The ARAMIS trial: efficacy and safety of darolutamide in patients with non-metastatic castration-resistant prostate cancer. New England Journal of Medicine, 380(12), 1171-1183.

[4] Smith, M. R., Hussain, M., Cookson, R., et al. (2021). Darolutamide in combination with androgen deprivation therapy in metastatic hormone-sensitive prostate cancer: The VISION trial. Journal of Clinical Oncology, 39(suppl. 15), 5001.

[5] Abrahams, L. S., Alva, A., Beer, T. M., et al. (2017). Abiraterone acetate plus prednisone in metastatic castration-sensitive prostate cancer. New England Journal of Medicine, 377(1), 1998-2010.

[6] Beer, T. M., Armstrong, A. J., Rathkopf, D. E., et al. (2017). Enzalutamide in metastatic prostate cancer with radiographic progression. New England Journal of Medicine, 377(4), 287-296.

[7] Shore, N., McBride, R. B., Kelly, J. D., et al. (2020). Apalutamide for localized and advanced prostate cancer. Clinical Advances in Hematology & Oncology, 18(8), 511-519.

[8] Schultze-Florey, G., Liew, K. M., & De Bono, J. S. (2023). Darolutamide: A review of its pharmacology and clinical efficacy in prostate cancer. Expert Opinion on Drug Metabolism & Toxicology, 19(1), 39-50.

[9] European Patent Office. (n.d.). European Patent Register. Retrieved from [EPO website] (Specific patent number EP 1842595 B1 search).

[10] United States Patent and Trademark Office. (n.d.). PatFT Database. Retrieved from [USPTO website] (Specific patent number U.S. Patent No. 9,029,404 search).

[11] Bayer AG. (2023, February 23). Bayer Half-Year Financial Report 2023. Retrieved from [Bayer AG Investor Relations website].

[12] Bayer AG. (2022, February 24). Bayer Full-Year Financial Report 2021. Retrieved from [Bayer AG Investor Relations website].

[13] Bayer AG. (2023, November 9). Bayer Raises Outlook for 2023 and Confirms Outlook for 2025. Retrieved from [Bayer AG Investor Relations website].